Products - Eye conditions | Topic

Showing 21 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
15 September 2026
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
11 November 2026
Monofocal intraocular lenses for cataract surgery
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
10 March 2027
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Teprotumumab for treating thyroid eye disease [ID6432]
Status:
Deferred
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ianalumab for treating active Sjogren's syndrome [ID6634]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Satralizumab for treating thyroid eye disease [ID6648]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vamikibart for treating uveitic macular oedema [ID6671]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Deucravacitinib for treating active Sjogren's syndrome [ID6715]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Miniature lens system implantation for advanced age-related macular degeneration
Status:
Awaiting development
Programme:
HealthTech guidance
Expected publication date:
TBC
Excimer Laser Trabeculotomy (ELT) for glaucoma
Status:
Awaiting development
Programme:
HealthTech guidance
Expected publication date:
TBC
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Eye conditions Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 21 products

Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

Monofocal intraocular lenses for cataract surgery

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Abicipar pegol for treating wet age-related macular degeneration [ID1533]

Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

Teprotumumab for treating thyroid eye disease [ID6432]

Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

Ianalumab for treating active Sjogren's syndrome [ID6634]

Satralizumab for treating thyroid eye disease [ID6648]

Vamikibart for treating uveitic macular oedema [ID6671]

Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]

OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]

Deucravacitinib for treating active Sjogren's syndrome [ID6715]

Miniature lens system implantation for advanced age-related macular degeneration

Excimer Laser Trabeculotomy (ELT) for glaucoma

Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

Eye conditions Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 21 products

Product type
1 selected

New and updated
1 selected